Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study.
about
Targeted Therapies in Adult B-Cell MalignanciesProfile of atacicept and its potential in the treatment of systemic lupus erythematosusMany multiple myelomas: making more of the molecular mayhemMolecular pathogenesis of multiple myeloma: basic and clinical updatesPotent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myelomaDevelopment of Novel Immunotherapies for Multiple MyelomaReview of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patientsSerum soluble TACI, a BLyS receptor, is a powerful prognostic marker of outcome in chronic lymphocytic leukemia.Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies.Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB.A critical role for the NFkB pathway in multiple myeloma.Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.New Therapeutic Approaches for Waldenstrom MacroglobulinemiaAntibody-based therapies in multiple myelomaDendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?Molecular pathogenesis of multiple myeloma and its premalignant precursor.Clinical targeting of the TNF and TNFR superfamiliesAPRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myelomaBAFF and APRIL as TNF superfamily molecules and angiogenesis parallel progression of human multiple myeloma.The kinase NIK as a therapeutic target in multiple myeloma.Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma.Atacicept as an investigated therapy for rheumatoid arthritis.B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?Targeting B-cell maturation antigen in multiple myeloma.Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.Inhibiting TLR9 and other UNC93B1-dependent TLRs paradoxically increases accumulation of MYD88L265P plasmablasts in vivo.Positioning NK-kappaB in multiple myeloma.Emerging immune targets for the treatment of multiple myeloma.
P2860
Q26783195-20898519-7B9D-42CA-B0D6-8D1D90552B2CQ26849719-6F188494-F7AF-40FF-8F38-5C06F77B23BCQ26852892-73C8568A-E762-4E23-91DD-E7F9EA5FAE38Q27026205-E0D30E51-A176-497A-836E-FEC96CCA49F8Q27700745-FBFDD719-1A7E-42C8-B96D-7203027EB6ACQ28066890-8A626A6E-5BD2-45C3-8ED5-3315858DA5B4Q28291793-CE255CFD-678A-4547-881E-8D35C9334C62Q33417346-6AC88129-6513-4D79-AEC0-5644B5C77D77Q33564854-8BDC2954-C487-4D80-B97E-ADF4446B4FF5Q33889168-97265F52-6A35-4206-B067-1243AE81D39EQ34101051-7EA89AEC-78DA-4AA7-80E7-1C3613D14463Q34165181-F41D80B7-4016-414D-8E32-26E16F48E07FQ34263870-9A6A184C-C270-468A-BCE7-D854CFE723E9Q35176177-20304AE6-34F7-4F1C-9566-A760DE0B4552Q35431150-18EB22C6-5B30-4A5C-82CA-5CEE83F6BAABQ35584599-6A265149-5221-4655-BE6B-7E30EE2EBF6EQ36290238-8221DCB1-939E-4460-9FDA-1D4AE00B4C10Q36762882-860E3769-2FAF-42F3-BB55-5F3B9EF7477FQ37035836-1EEF554E-4A79-4FC3-8D89-A274D5C18843Q37054982-68EAB755-FC08-4E69-9268-1AA450BA06EBQ37622417-3BC1CBDA-4448-4A13-A86E-C4303902B1D3Q37825898-5CECC1E1-7C51-4FFF-86C9-1F90678C26BAQ38090691-12C62488-06C6-4070-A1FE-742F6F9A8A58Q38235570-1419608A-0AB8-4CAE-9B27-EE8FE27CA8CAQ38365867-EC03E119-B895-4CDB-A6C6-C4FB1F5EC1BDQ38586922-FAE607DA-2136-40D0-A1AF-07FE278AF080Q38601582-D551EC8C-EDB8-4366-866B-19778C4DEA59Q38961202-FFC15C2D-949B-4871-95E2-442D5C8F10C5Q41168768-9049FF96-4EBA-4EB8-95E0-0859A0EE5AACQ41190031-03685FC4-8B33-4D7A-AC03-5E906954BA54Q50025144-8E8CF68B-BE88-4674-B9CA-19D9424549F0
P2860
Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Atacicept in relapsed/refracto ...... globulinemia: a phase I study.
@en
Atacicept in relapsed/refracto ...... globulinemia: a phase I study.
@nl
type
label
Atacicept in relapsed/refracto ...... globulinemia: a phase I study.
@en
Atacicept in relapsed/refracto ...... globulinemia: a phase I study.
@nl
prefLabel
Atacicept in relapsed/refracto ...... globulinemia: a phase I study.
@en
Atacicept in relapsed/refracto ...... globulinemia: a phase I study.
@nl
P2093
P2860
P356
P1476
Atacicept in relapsed/refracto ...... globulinemia: a phase I study.
@en
P2093
G Mordenti
G Requirand
H Goldschmidt
I Nestorov
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605241
P407
P577
2009-10-01T00:00:00Z
P5875
P6179
1048929076